Lifecore Net Receivables vs Retained Earnings Analysis
LFCR Stock | 5.91 0.15 2.48% |
Lifecore Biomedical financial indicator trend analysis is infinitely more than just investigating Lifecore Biomedical recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lifecore Biomedical is a good investment. Please check the relationship between Lifecore Biomedical Net Receivables and its Retained Earnings accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.
Net Receivables vs Retained Earnings
Net Receivables vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lifecore Biomedical Net Receivables account and Retained Earnings. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Lifecore Biomedical's Net Receivables and Retained Earnings is 0.5. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Lifecore Biomedical, assuming nothing else is changed. The correlation between historical values of Lifecore Biomedical's Net Receivables and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Lifecore Biomedical are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Net Receivables i.e., Lifecore Biomedical's Net Receivables and Retained Earnings go up and down completely randomly.
Correlation Coefficient | 0.5 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Net Receivables
Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from Lifecore Biomedical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lifecore Biomedical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.At this time, Lifecore Biomedical's Selling General Administrative is relatively stable compared to the past year. As of 06/08/2024, Tax Provision is likely to grow to about 363.5 K, while Enterprise Value Over EBITDA is likely to drop 7.98.
2021 | 2023 | 2024 (projected) | Total Revenue | 185.8M | 103.3M | 98.1M | Interest Expense | 17.4M | 18.2M | 19.1M |
Lifecore Biomedical fundamental ratios Correlations
Click cells to compare fundamentals
Lifecore Biomedical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lifecore Biomedical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 541.3M | 502.9M | 295.2M | 295.4M | 255.2M | 248.0M | |
Short Long Term Debt Total | 221.1M | 221.4M | 153.2M | 153.1M | 112.7M | 65.2M | |
Other Current Liab | 19.0M | 20.3M | 16.9M | 17.1M | 10.8M | 12.6M | |
Total Current Liabilities | 164.4M | 101.9M | 79.2M | 79.4M | 38.8M | 55.0M | |
Total Stockholder Equity | 231.0M | 202.8M | 107.9M | 108.1M | (1.8M) | (1.7M) | |
Property Plant And Equipment Net | 200.0M | 217.7M | 200.4M | 139.0M | 134.6M | 78.2M | |
Net Debt | 220.8M | 220.1M | 151.5M | 151.4M | 93.6M | 98.3M | |
Retained Earnings | 71.2M | 38.6M | (58.9M) | (58.7M) | (176.2M) | (167.4M) | |
Accounts Payable | 54.0M | 51.6M | 47.6M | 15.8M | 22.1M | 23.6M | |
Cash | 1.1M | 360K | 1.3M | 1.6M | 19.1M | 10.9M | |
Non Current Assets Total | 386.1M | 384.2M | 354.6M | 171.4M | 155.9M | 161.1M | |
Non Currrent Assets Other | (9.7M) | (25.3M) | (26.7M) | 3.0M | 3.2M | 3.4M | |
Cash And Short Term Investments | 1.1M | 360K | 1.3M | 1.6M | 19.1M | 13.4M | |
Common Stock Shares Outstanding | 29.2M | 29.3M | 29.5M | 29.5M | 30.0M | 26.2M | |
Liabilities And Stockholders Equity | 541.3M | 502.9M | 295.2M | 295.4M | 255.2M | 248.0M | |
Non Current Liabilities Total | 145.9M | 198.3M | 108.0M | 107.9M | 218.2M | 229.1M | |
Inventory | 66.3M | 69.7M | 66.8M | 67.0M | 45.4M | 26.8M | |
Other Current Assets | 8.3M | 14.2M | 7.4M | 7.1M | 5.1M | 8.8M | |
Other Stockholder Equity | 160.3M | 162.6M | 165.5M | 167.4M | 174.3M | 121.7M | |
Total Liab | 310.3M | 300.1M | 187.2M | 187.3M | 257.0M | 269.8M | |
Total Current Assets | 157.1M | 148.3M | 123.7M | 124.0M | 99.3M | 86.9M | |
Short Term Debt | 61.8M | 93.4M | 32.9M | 45.6M | 1.8M | 1.7M | |
Net Receivables | 76.2M | 70.0M | 48.2M | 48.3M | 29.7M | 35.3M | |
Intangible Assets | 45.2M | 38.1M | 36.1M | 15.6M | 4.2M | 4.0M | |
Current Deferred Revenue | 499K | 352K | 1.1M | 919K | 4.1M | 4.3M | |
Good Will | 54.5M | 76.7M | 69.4M | 13.9M | 16.0M | 15.2M | |
Accumulated Other Comprehensive Income | 64K | (2.8M) | (1.4M) | (586K) | (39.2M) | (37.3M) | |
Other Liab | 14.6M | 11.3M | 422K | 3.5M | 3.1M | 3.0M | |
Net Tangible Assets | 123.6M | 143.2M | 78.5M | (19.9M) | (17.9M) | (17.0M) | |
Other Assets | 2.2M | 157.7M | 3.0M | 3.2M | 3.7M | 3.5M | |
Long Term Debt | 101.4M | 164.9M | 97.6M | 101.3M | 116.5M | 121.5M | |
Capital Lease Obligations | 30.8M | 27.5M | 15.0M | 11.0M | 9.9M | 14.1M | |
Net Invested Capital | 421.4M | 396.7M | 246.1M | 99.9M | 89.9M | 85.4M | |
Short Long Term Debt | 89.0M | 29M | 40.6M | 488K | 439.2K | 417.2K | |
Non Current Liabilities Other | 4.6M | 3.6M | 190K | 3.1M | 2.8M | 2.1M | |
Net Working Capital | (7.3M) | 46.4M | 44.5M | 60.5M | 69.6M | 73.0M | |
Property Plant Equipment | 217.7M | 137.4M | 139.0M | 134.6M | 121.1M | 132.6M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.